Passa al contenuto
Merck

ABCs of Neonatal Cardiac Anesthesia.

Artificial organs (2013-01-12)
Chris Chin
ABSTRACT

Congenital heart disease (CHD) is relatively common and there are treatment options for virtually every form of CHD. With good care, the majority of babies can survive to adulthood; however, CHD remains a significant cause of death in infancy and neonates are especially vulnerable. In order to manage these patients, a clear understanding of the underlying pathophysiology and the planned surgical procedure is important. However, attention to detail and meticulous care are equally important, and, in addition, there are several management strategies that may standardize practice and can improve outcome.

MATERIALI
N° Catalogo
Marchio
Descrizione del prodotto

Sigma-Aldrich
Solfato di magnesio, anhydrous, ReagentPlus®, ≥99.5%
Sigma-Aldrich
Solfato di magnesio eptaidrato, ACS reagent, ≥98%
Sigma-Aldrich
Solfato di magnesio eptaidrato, ReagentPlus®, ≥99.0%
Sigma-Aldrich
Solfato di magnesio eptaidrato, BioReagent, for molecular biology, suitable for plant cell culture, ≥99.0%
Sigma-Aldrich
Solfato di magnesio, BioReagent, suitable for cell culture, suitable for insect cell culture
Sigma-Aldrich
Solfato di magnesio, puriss. p.a., drying agent, anhydrous, ≥98.0% (KT), powder (very fine)
Sigma-Aldrich
Magnesium sulfate solution, for molecular biology, 1.00 M±0.04 M
Sigma-Aldrich
Solfato di magnesio eptaidrato, BioUltra, ≥99.5% (KT)
Sigma-Aldrich
Magnesium sulfate solution, BioUltra, for molecular biology
Sigma-Aldrich
Solfato di magnesio, ≥99.99% trace metals basis
Sigma-Aldrich
Solfato di magnesio eptaidrato, BioXtra, ≥99.0%